131 related articles for article (PubMed ID: 38342078)
1. Discovery of novel MAT2A inhibitors by an allosteric site-compatible fragment growing approach.
Gao F; Ding X; Cao Z; Zhu W; Fan Y; Steurer B; Wang H; Cai X; Zhang M; Aliper A; Ren F; Ding X; Zhavoronkov A
Bioorg Med Chem; 2024 Feb; 100():117633. PubMed ID: 38342078
[TBL] [Abstract][Full Text] [Related]
2. Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A.
Quinlan CL; Kaiser SE; Bolaños B; Nowlin D; Grantner R; Karlicek-Bryant S; Feng JL; Jenkinson S; Freeman-Cook K; Dann SG; Wang X; Wells PA; Fantin VR; Stewart AE; Grant SK
Nat Chem Biol; 2017 Jul; 13(7):785-792. PubMed ID: 28553945
[TBL] [Abstract][Full Text] [Related]
3. Overview of Methionine Adenosyltransferase 2A (MAT2A) as an Anticancer Target: Structure, Function, and Inhibitors.
Li C; Gui G; Zhang L; Qin A; Zhou C; Zha X
J Med Chem; 2022 Jul; 65(14):9531-9547. PubMed ID: 35796517
[TBL] [Abstract][Full Text] [Related]
4. Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous
Konteatis Z; Travins J; Gross S; Marjon K; Barnett A; Mandley E; Nicolay B; Nagaraja R; Chen Y; Sun Y; Liu Z; Yu J; Ye Z; Jiang F; Wei W; Fang C; Gao Y; Kalev P; Hyer ML; DeLaBarre B; Jin L; Padyana AK; Dang L; Murtie J; Biller SA; Sui Z; Marks KM
J Med Chem; 2021 Apr; 64(8):4430-4449. PubMed ID: 33829783
[TBL] [Abstract][Full Text] [Related]
5. Fragment-Based Design of a Potent MAT2a Inhibitor and
De Fusco C; Schimpl M; Börjesson U; Cheung T; Collie I; Evans L; Narasimhan P; Stubbs C; Vazquez-Chantada M; Wagner DJ; Grondine M; Sanders MG; Tentarelli S; Underwood E; Argyrou A; Smith JM; Lynch JT; Chiarparin E; Robb G; Bagal SK; Scott JS
J Med Chem; 2021 May; 64(10):6814-6826. PubMed ID: 33900758
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel methionine adenosyltransferase 2A (MAT2A) allosteric inhibitors by structure-based virtual screening.
Kalliokoski T; Kettunen H; Kumpulainen E; Kettunen E; Thieulin-Pardo G; Neumann L; Thomsen M; Paul R; Malyutina A; Georgiadou M
Bioorg Med Chem Lett; 2023 Oct; 94():129450. PubMed ID: 37591318
[TBL] [Abstract][Full Text] [Related]
7. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition.
Bedard GT; Gilaj N; Peregrina K; Brew I; Tosti E; Shaffer K; Tyler PC; Edelmann W; Augenlicht LH; Schramm VL
J Biol Chem; 2024 Jan; 300(1):105492. PubMed ID: 38000655
[TBL] [Abstract][Full Text] [Related]
8. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
9. Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability.
Zhang S; Qing L; Wang Z; Zhang Y; Li Y; Fang H; Liu Y; He H
J Med Chem; 2023 Apr; 66(7):4849-4867. PubMed ID: 36961373
[TBL] [Abstract][Full Text] [Related]
10. Targeting the methionine-methionine adenosyl transferase 2A- S -adenosyl methionine axis for cancer therapy.
Guo J; Yang Y; Buettner R; Rosen ST
Curr Opin Oncol; 2022 Sep; 34(5):546-551. PubMed ID: 35788128
[TBL] [Abstract][Full Text] [Related]
11. A patent review of MAT2a inhibitors (2018-2021).
Atkinson SJ; Evans L; Scott JS
Expert Opin Ther Pat; 2022 Oct; 32(10):1043-1053. PubMed ID: 36043503
[TBL] [Abstract][Full Text] [Related]
12. MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
Kalev P; Hyer ML; Gross S; Konteatis Z; Chen CC; Fletcher M; Lein M; Aguado-Fraile E; Frank V; Barnett A; Mandley E; Goldford J; Chen Y; Sellers K; Hayes S; Lizotte K; Quang P; Tuncay Y; Clasquin M; Peters R; Weier J; Simone E; Murtie J; Liu W; Nagaraja R; Dang L; Sui Z; Biller SA; Travins J; Marks KM; Marjon K
Cancer Cell; 2021 Feb; 39(2):209-224.e11. PubMed ID: 33450196
[TBL] [Abstract][Full Text] [Related]
13. Human Mat2A Uses an Ordered Kinetic Mechanism and Is Stabilized but Not Regulated by Mat2B.
Bailey J; Douglas H; Masino L; de Carvalho LPS; Argyrou A
Biochemistry; 2021 Nov; 60(47):3621-3632. PubMed ID: 34780697
[TBL] [Abstract][Full Text] [Related]
14. The Transition-State Structure for Human MAT2A from Isotope Effects.
Firestone RS; Schramm VL
J Am Chem Soc; 2017 Oct; 139(39):13754-13760. PubMed ID: 28880543
[TBL] [Abstract][Full Text] [Related]
15. S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells.
Strekalova E; Malin D; Weisenhorn EMM; Russell JD; Hoelper D; Jain A; Coon JJ; Lewis PW; Cryns VL
Breast Cancer Res Treat; 2019 May; 175(1):39-50. PubMed ID: 30712196
[TBL] [Abstract][Full Text] [Related]
16. The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity.
Xuan YF; Lu S; Ou YJ; Bao XB; Huan XJ; Song SS; Miao ZH; Wang YQ
Biochem Biophys Res Commun; 2024 Jul; 716():150011. PubMed ID: 38704890
[TBL] [Abstract][Full Text] [Related]
17. mTORC1-independent translation control in mammalian cells by methionine adenosyltransferase 2A and S-adenosylmethionine.
Alam M; Shima H; Matsuo Y; Long NC; Matsumoto M; Ishii Y; Sato N; Sugiyama T; Nobuta R; Hashimoto S; Liu L; Kaneko MK; Kato Y; Inada T; Igarashi K
J Biol Chem; 2022 Jul; 298(7):102084. PubMed ID: 35636512
[TBL] [Abstract][Full Text] [Related]
18. Development of a Series of Pyrrolopyridone MAT2A Inhibitors.
Atkinson SJ; Bagal SK; Argyrou A; Askin S; Cheung T; Chiarparin E; Coen M; Collie IT; Dale IL; De Fusco C; Dillman K; Evans L; Feron LJ; Foster AJ; Grondine M; Kantae V; Lamont GM; Lamont S; Lynch JT; Nilsson Lill S; Robb GR; Saeh J; Schimpl M; Scott JS; Smith J; Srinivasan B; Tentarelli S; Vazquez-Chantada M; Wagner D; Walsh JJ; Watson D; Williamson B
J Med Chem; 2024 Mar; 67(6):4541-4559. PubMed ID: 38466661
[TBL] [Abstract][Full Text] [Related]
19. Methionine adenosyltransferase 2A/2B and methylation: gene sequence variation and functional genomics.
Nordgren KK; Peng Y; Pelleymounter LL; Moon I; Abo R; Feng Q; Eckloff B; Yee VC; Wieben E; Weinshilboum RM
Drug Metab Dispos; 2011 Nov; 39(11):2135-47. PubMed ID: 21813468
[TBL] [Abstract][Full Text] [Related]
20. Mechanism and Inhibition of Human Methionine Adenosyltransferase 2A.
Niland CN; Ghosh A; Cahill SM; Schramm VL
Biochemistry; 2021 Mar; 60(10):791-801. PubMed ID: 33656855
[No Abstract] [Full Text] [Related]
[Next] [New Search]
